DelSiTech and C-Tri team on long acting peptide delivery

By Staff Reporter

- Last updated on GMT

GettyImages/Golden_Brown
GettyImages/Golden_Brown

Related tags: Protein

Korean drug firm C-Tri has teamed with Finnish drug delivery firm DelSiTech to develop a peptide drug for oncology.

C-Tri Co. Ltd peptide candidate – NHM-CT-007 – will use DelSiTech’s drug delivery platform, based on a silica (SiO2) matrix into which the molecule is embedded, Cora Griffin, BD director at DelSiTech told us.

“Silica Matrix is an advanced controlled and long acting delivery technology for parenteral and local administration of injectable depot and implant dosage forms​,” she said.

“The resulting Matrix is nanoporous, biocompatible and it can be designed to biodegrade by matrix dissolution at the desired rate to ensure a tightly controlled release of the active substance over periods of days up to many months or a year.”

She added the technology allows very tightly controlled release as well as offering the environmental advantage of being biodegradable.

“When is degrades, it does so into silicic acid, a very weak acid which does not alter the pH of the local environment.”

Under the terms of the deal, DelSiTech will lead the development work for NHM-CT-007 in Finland and other parts of Europe. Financial details have not been disclosed.

The platform can be applied to all types of molecules – small molecules, peptides, proteins, antibodies, viruses, RNA, DNA – and Wan-joo Kim, CEO of C-Tri said it was looking to apply the tech to other peptides in its pipeline.

Related topics: Drug Delivery

Related news

Follow us

Products

View more

Webinars